Literature DB >> 17178684

Ultrafast time-resolved contrast-enhanced 3D pulmonary venous cardiovascular magnetic resonance angiography using SENSE combined with CENTRA-keyhole.

Hermann Körperich1, Jürgen Gieseke, Hermann Esdorn, Andreas Peterschröder, Romhild Hoogeveen, Peter Barth, Matthias Peuster, Hans Meyer, Samir Sarikouch, Philipp Beerbaum.   

Abstract

PURPOSE: To evaluate the diagnostic benefit of time-resolved CENTRA-keyhole contrast-enhanced cardiovascular magnetic resonance angiography (CE-CMRA) for improving arterial-venous separation of pulmonary vessels.
METHODS: Twenty-three patients (18 males; age = 58 +/- 11y) after radiofrequency pulmonary vein isolation to treat atrial fibrillation were examined using CENTRA-keyhole based multi-phase 3D CE-CMRA yielding 6 near-isotropic 3D datasets every 1.6 s (50-60 coronal partitions, 1.4 x 1.4 x 1.3 mm, SENSE-factor 3). Results were compared with conventional non-keyhole CE-CMRA (identical parameters, SENSE-factor 2).
RESULTS: Data acquisition was accelerated by a speedup factor of approximately 9 compared with the reference CE-CMRA (SENSE 1.5*, keyhole 6*). No pulmonary venous stenoses were detected by either method, overall pulmonary venous diameters were 17.1 +/- 3.6 mm. Applying Bland-Altman analysis, vessel diameters differed by a mean of 0.1 mm + 2.1 mm/-2.0 mm (mean +/- 2 SD), indicating close agreement between both techniques. Interobserver variability was higher for CENTRA-keyhole (mean = 0.1 mm; mean +/- 2 SD: +2.5 mm/-2.3 mm) compared to conventional technique (0.0 mm; +1.6 mm/-1.5 mm), corresponding to a percentual deviation (mean +/- 2 SD) of the mean diameter of approximately +/- 15% (keyhole CE-CMRA) and +/- 10% (conventional CE-CMRA), respectively. Using keyhole-based time-resolved CE-CMRA, the contrast between pulmonary veins versus aorta/pulmonary artery was significantly increased (p < 0.05), which improved vessel depiction. In 12 cases, the contrast bolus arrival was delayed in one of the pulmonary veins by 1 dynamic frame (= 1.6 seconds); in 7 cases by 2 frames (= 3.2 seconds) and in 1 subject by 3 frames (= 4.8 seconds). The bolus usually appeared first in the upper right pulmonary vein whereas a delay occurred most often in the lower left pulmonary vein.
CONCLUSIONS: Conventional CE-CMRA may be advantageous for accurate vessel size measures as evidenced by superior interobserver reproducibility in this study. Multi-dynamic CE-CMRA using CENTRA-keyhole with SENSE, however, allows for improved arterio-venous separation of pulmonary vessels and additional dynamical information on pulmonary venous perfusion, while maintaining high spatial resolution. Exact bolus timing is no longer needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17178684     DOI: 10.1080/10976640600737664

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  4 in total

1.  Quality-evaluation scheme for cerebral time-resolved 3D contrast-enhanced MR angiography techniques.

Authors:  H Raoult; J-C Ferré; X Morandi; B Carsin-Nicol; M Carsin; M Cuggia; M Law; J-Y Gauvrit
Journal:  AJNR Am J Neuroradiol       Date:  2010-05-06       Impact factor: 3.825

2.  Time-resolved magnetic resonance angiography: evaluation of intrapulmonary circulation parameters in pulmonary arterial hypertension.

Authors:  Hyun J Jeong; Parmede Vakil; John J Sheehan; Sanjiv J Shah; Michael Cuttica; James C Carr; Timothy J Carroll; Amir Davarpanah
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

Review 3.  Radiologic review of acquired pulmonary vein stenosis in adults.

Authors:  Mauricio Galizia; Rahul Renapurkar; Lourdes Prieto; Michael Bolen; Joseph Azok; Charles T Lau; Ahmed H El-Sherief
Journal:  Cardiovasc Diagn Ther       Date:  2018-06

4.  A comparison of 4D time-resolved MRA with keyhole and 3D time-of-flight MRA at 3.0 T for the evaluation of cerebral aneurysms.

Authors:  Qian Wu; Ming-Hua Li
Journal:  BMC Neurol       Date:  2012-07-06       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.